“An area within healthcare to pay attention to is the smaller-cap biotech companies, as the pace of M&A activity in this area has picked up noticeably since May of this year. Axsome Therapeutics (AXSM) is a small-cap biotech company with a market cap of approximately $2 Billion that is developing novel therapies for central nervous system (CNS) disorders for which there are limited treatment options,” says Kevin Mahn. All on the TD Ameritrade Network.
Click here to watch the video on TD Ameritrade Network.
This link is to a third-party website and has no affiliation with Hennion & Walsh, Inc. It is provided for informational purposes only.
Disclosure: Hennion & Walsh Asset Management currently has allocations within its managed money program, and Hennion & Walsh currently has allocations within certain SmartTrust® Unit Investment Trusts (UITs), consistent with several of the investment areas discussed during this interview.